Cerus Corporation

Concord, CA 94520

SBIR Award Summary

Total Number of Awards 22
Total Value of Awards $3.14MM
First Award Date 09/30/93
Most Recent Award Date 09/01/06

Key Personnel

Last Name Name Awards Contact
Wiesehahn Gary P Wiesehahn 1
Wollowitz Susan Wollowitz 2
Lin Lily Lin 3
Hearst John E Hearst 6
Giedlin Martin A Giedlin 2
Dubensky Thomas W. Dubensky 3
Brockstedt Dirk G. Brockstedt 2
Roback John D Roback 1
Corash Lawrence Corash 2

22 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/06 - 12/31/07

DESCRIPTION (provided by applicant): Pancreatic and ovarian cancers are among the most aggressive and lethal malignancies, and represent a major unmet medical need. To wit: (1) pancreatic cancer patients have a 5-year survival rate of less than 5% and the 32,000 new cases per year in the U.S. is close to the number of annual deaths; and, (2) ova...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/06 - 12/31/07

DESCRIPTION (provided by applicant): Recent progress in molecular and cellular immunology has advanced our understanding of tumor-host interactions and opened extraordinary opportunities for the development of anti-tumor immunotherapies. The identification of tumor antigens over the last decade for many tumors, including ovarian, has laid the f...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/06 - 02/28/09

DESCRIPTION (provided by applicant): Delayed reconstitution of antigen-specific immunity following allogeneic hematopoietic stem cell transplantation (HSCT) predisposes patients to opportunistic infections and tumor recurrence. To address these problems, we are developing a vaccination methodology using a non-replicating but highly immunogenic L...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/05 - 08/31/06

DESCRIPTION (provided by applicant): Pancreatic and ovarian cancers are among the most aggressive and lethal malignancies, and represent a major unmet medical need. To wit: (1) pancreatic cancer patients have a 5-year survival rate of less than 5% and the 32,000 new cases per year in the U.S. is close to the number of annual deaths; and, (2) ova...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/05 - 05/31/06

DESCRIPTION (provided by applicant): Recent progress in molecular and cellular immunology has advanced our understanding of tumor-host interactions and opened extraordinary opportunities for the development of anti-tumor immunotherapies. The identification of tumor antigens over the last decade for many tumors, including ovarian, has laid the f...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/15/05 - 01/14/08

DESCRIPTION (provided by applicant): Amotosalen-HCI is a proprietary psoralen compound owned by Cerus Corporation, which has been developed for the inactivation of pathogens for the blood transfusion industry. Amotosalen-HCI is used in a photochemical process for the inactivation of pathogens in platelet concentrates and in fresh frozen plasma. ...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/04 - 08/31/07

DESCRIPTION (provided by applicant): This is a combined Phase I/II SBIR Fast-Track proposal. Bone marrow transplantation has the potential of providing a complete cure of the disease symptoms of hematologic malignancies and, ultimately, with an appropriate safety profile, the symptoms of hemoglobinopathies as well. Even in the case of related fu...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/04 - 09/30/04

DESCRIPTION (provided by applicant): Dendritic cell (DC)-based immunotherapy has yielded encouraging evidence of providing clinical benefit for the treatment of a broad range of malignancies. Several strategies are being developed to isolate autologous DC, and load them with antigen or peptides ex vivo. Advances in the understanding of immune...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/05/04 - 02/28/06

DESCRIPTION (provided by applicant): The ability to repair DNA damage is critical to the survival of a cell, whether normal or cancerous. Upon damage, DNA repair genes and other factors are activated either to remove the damage, or, if the DNA damage is too extensive, to initiate programmed cell death. The majority of current anticancer chemothe...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/15/04 - 01/14/05

DESCRIPTION (provided by applicant): Amotosalen-HCI is a proprietary psoralen compound owned by Cerus Corporation, which has been developed for the inactivation of pathogens for the blood transfusion industry. Amotosalen-HCI is used in a photochemical process for the inactivation of pathogens in platelet concentrates and in fresh frozen plasma. ...

Load More